Grade: Pharmaceutical Grade

Factory Location: Anqing,Anhui Province

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 150kgs

Packaging Information: 25kgs per drum

Delivery Lead Time: deliver in two weeks

Sample Provided: yes

Payment Terms: T/T

Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the potential treatment of neurological disorders, namely epilepsy and neuropathic pain. By December 2003, UCB reported that phase II epilepsy trials had begun